Deliver Your News to the World

Clinical research using Imagine Eyes’ products for cellular-level retinal imaging takes center stage in May 2013

Cellular-level retinal imaging with Imagine Eyes’ products is breaking new ground in clinical research and will be at the heart of over 50 scientific presentations ranging from retinal anatomy to insightful data on sight-threatening diseases.


Seattle, WA and Orsay, France, May 05, 2013 – Imagine Eyes, the pioneer in cellular-level retinal imaging, is proud to announce that its products have been used by leading clinical researchers to produce over 50 works to be presented during the month of May 2013 alone.

“These presentations confirm that the rtx1* is becoming an indispensable tool for doctors that need to study the retina at a level of detail that remains invisible to other imaging products” states Nicolas Chateau, CEO of Imagine Eyes. “What we’re seeing is comparable to the revolutions fostered by the advent of OCT where the early results sought to define the clinical applications of those technologies. Much of what is being presented either validates that what is seen with the rtx1 is coherent with accepted anatomical data or highlights the rtx1’s unique contribution to visualizing changes in retinal morphology caused by specific diseases. The ensemble of the body of work is as impressive as it is promising.”

“We are very happy to see that our customers have taken full advantage of the new software features we delivered last year” notes Xavier Levecq, Imagine Eyes’ CTO. “In addition to enhancing the software interface’s ergonomics, we provided significantly improved image processing features and quantitative image analysis tools. The latter have enabled customers to measure cone density, inter-cone spacing and cone mosaic regularity metrics – all of which are displayed both as descriptive statistics and as easy to interpret color charts.”

“The new processing algorithm has vastly improved the image quality of the cone mosaic.  We are even seeing what we think might be rods in some cases” notes Mark Pennesi, Assistant Professor, Director of Ophthalmic Imaging at the Casey Eye Institute at the Oregon Health & Science University in Portland, OR.

“As a member of Imagine Eyes’ Medical Advisory Board, I have watched the rtx1 develop from an early-stage prototype into a commercial product” remarks José Sahel, Chairman of Ophthalmology at France’s Quinze-Vingts National Eye Hospital. “The outstanding results being presented by groups from around the world that use the rtx1 are sure to inspire many others to incorporate the product’s unique functionalities into their clinical research.”

To see a list of presentations at the 2013 annual meeting of the Association for Research in Vision and Ophthalmology in Seattle from May 5-9 2013, please visit For a list of presentations at the French Ophthalmology Society (Société Française d’Ophtalmologie “SFO”) annual meeting in Paris from May 11-14, please visit

To see a live demonstration of the rtx1 Adaptive Optics Retinal Camera*, visit Imagine Eyes at ARVO-ISIE on stand 8, at the ARVO annual meeting exhibit on stand 1115 or at the SFO annual meeting on the Sanotek stand F16. For more information, please visit or call +33 (0)1 64 86 15 66.


About Imagine Eyes – Imagine Eyes develops ophthalmic instruments that analyze the eye at the microscopic scale. Conceived from a revolutionary technology, adaptive optics, its products enables cellular-level retinal imaging, precision measurement of the eyes’ refractive errors and vision simulation. Founded in 2003 in Orsay, France by photonics and ophthalmic industry specialists, the company is ISO 9001 and 13485 certified. It maintains its position as a technology leader thanks to its intensive R&D program, broad portfolio of patents and the marketing of cutting-edge products that have been rapidly adopted by its customers.

* CE Marked and Shonin approved. The rtx1 has not received FDA clearance.


 adaptive optics
 retinal imaging
 geographic atrophy

This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.